Relapsed Multiple Myeloma

Also known as: Multiple Myeloma, Relapsed / Relapsed Multiple Mieloma

DrugDrug NameDrug Description
DB09331DaratumumabA CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma.
DB16665Idecabtagene vicleucelAn autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma.
DrugDrug NamePhaseStatusCount
DB00188Bortezomib1Completed1
DB08889Carfilzomib1Completed2
DB00482Celecoxib1Completed1
DB01234Dexamethasone1Completed1
DB00099Filgrastim1Active Not Recruiting1
DB01167Itraconazole1Completed1
DB00480Lenalidomide1Completed2
DB01042Melphalan1Active Not Recruiting1
DB11836Sapanisertib1Completed1
DB00755Tretinoin1Completed1
DB023422-Methoxyestradiol2Completed1
DB00531Cyclophosphamide2Active Not Recruiting1
DB00531Cyclophosphamide2Recruiting1
DB01234Dexamethasone2Active Not Recruiting1
DB01073Fludarabine2Recruiting1
DB14811Isatuximab2Not Yet Recruiting1
DB09570Ixazomib2Active Not Recruiting1
DB00688Mycophenolate mofetil2Recruiting1
DB09035Nivolumab2Active Not Recruiting1
DB00877Sirolimus2Recruiting1
DB08889Carfilzomib3Active Not Recruiting1
DB08889Carfilzomib3Completed1
DB09331Daratumumab3Active Not Recruiting1
DB01234Dexamethasone3Active Not Recruiting2
DB01234Dexamethasone3Completed1
DB09570Ixazomib3Active Not Recruiting1
DB00480Lenalidomide3Active Not Recruiting1
DB00480Lenalidomide3Completed1